More about GLP1 agonists
and why to consider microdosing with us!

GLP1 agonists like semiglutide and tirzepatide are taking the world by storm and not just because of their effects on weight loss. People have been reporting improvements in a number of other conditions including chronic pain and chronic inflammatory conditions. This has lead to new research.

Many have argued that the doses used thus far may shut off the body's own production of the GLP1 peptides so people then become dependent on the medications for life. Microdosing refers to giving very very low does of a medication to prevent side effects and shutting down endogenous peptide production while still getting the intended effects.

At Olakino Center for Lifestyle Medicine, we offer TIRZEPATIDE a GLP1 and GIP agonist at reduced doses. At these doses weight loss is still possible as well as potential reduction of symptoms associated with many other conditions with reduced concern for side effects. Many report clearer thinking and improved energy.

We sell both monthly packages for medication only and 3 monthly packages with additional comprehensive support with Dr Canyon and her team.

BOOK A FREE CONSULTATION TODAY TO SEE IF THIS OR OUR OTHER PACKAGES WILL SUIT YOUR NEEDS.

BOOK NOW

The Therapeutic Potential of GLP-1 Agonists: Beyond Diabetes Management

GLP-1 agonists, originally developed for the treatment of type 2 diabetes, have rapidly gained recognition for their broad therapeutic potential. These medications mimic the action of the naturally occurring hormone GLP-1, influencing glucose metabolism and offering a range of benefits across various medical conditions. Below, we explore how GLP-1 agonists are being utilized and researched across multiple health domains:

Type 2 Diabetes & Obesity

Primary Use in Diabetes:
GLP-1 agonists are well-established in managing type 2 diabetes by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. This multifaceted approach helps lower blood glucose levels and HbA1c, making them a cornerstone of diabetes care.

Weight Management:
In addition to glycemic control, GLP-1 agonists are highly effective in promoting weight loss. By reducing appetite and slowing the digestive process, these medications assist in significant weight reduction, particularly beneficial for individuals struggling with obesity.

Heart Health

Some GLP-1 agonists, such as liraglutide and semaglutide, have been shown to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes. These benefits extend beyond glycemic control, offering protection against heart disease and stroke.

Neurological Disorders

Parkinson’s Disease:
Emerging research suggests that GLP-1 agonists have neuroprotective properties that may slow the progression of Parkinson's disease. Early clinical trials have shown that these medications can improve motor function and potentially modify the course of the disease.

Alzheimer’s Disease:
GLP-1 agonists are being investigated for their potential to treat Alzheimer's disease, particularly due to their ability to improve brain insulin signaling and reduce neuroinflammation. Initial studies indicate that these drugs may help slow cognitive decline in patients with Alzheimer’s or mild cognitive impairment.

Mood Conditions

Depression and Anxiety:
Mood disorders such as depression and anxiety may also benefit from GLP-1 agonists. These medications exhibit anti-inflammatory and neuroprotective effects, which could alleviate symptoms of depression and anxiety, particularly in individuals with comorbid conditions like obesity or diabetes.

Chronic Pain & Inflammatory Conditions

Chronic Pain:
GLP-1 agonists have shown promise in reducing chronic pain, particularly in animal models of neuropathic pain. While human research is still limited, the anti-inflammatory and neuroprotective properties of these drugs suggest potential future applications in pain management.

Inflammatory Conditions:
The anti-inflammatory effects of GLP-1 agonists are being explored in various inflammatory diseases, including:

Atherosclerosis: Reducing inflammation to prevent the progression of heart disease.
Non-Alcoholic Fatty Liver Disease (NAFLD): Improving liver health by reducing liver fat and inflammation.
Rheumatoid Arthritis (RA): Potentially decreasing joint inflammation and damage.
Inflammatory Bowel Disease (IBD): Exploring their role in reducing intestinal inflammation in conditions like Crohn’s disease and ulcerative colitis.
Psoriasis: Investigating their impact on systemic inflammation in chronic skin conditions.
Chronic Kidney Disease (CKD): Slowing the progression of kidney damage by reducing inflammation.